MNK

Continued Strong Performance Driven by Growth in Acthar® Gel1 and XIAFLEX®2XIAFLEX Pipeline Advances: Plantar Fibromatosis sBLA Submission Expected in First Quarter 2027, Hammer Toe Phase 3 Study Enrollment Initiated Raises Full-Year Net Sales and Adjusted EBITDA Guidance on Higher XIAFLEX Growth Expectations and Acthar Gel StrengthConference Call and Webcast Today at 8:00 a.m. ET Third Quarter 2026 Highlights3Acthar Gel net sales of $227 millionXIAFLEX net sales of $164 millionNet sales from continuing operations of $550 millionLoss from continuing operations of $96 millionAdjusted EBITDA from continuing operations of $233 millionMerger synergies ahead of plan in 2026 and on track to achiev

DUBLIN, Nov. 5, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that two new presentations highlighting clinical trial and real-world evidence related to TERLIVAZ® (terlipressin) in treating hepatorenal syndrome-acute kidney injury (HRS-AKI) will be presented at The Liver Meeting®, the annual conference of the American Association for the Study of Liver Diseases (AASLD), taking place November 5-8, 2026. "We are pleased to share these new data, which continue to expand our understanding of hepatorenal syndrome-acute kidney injury and the potential impact of TERLIVAZ in clinical practice," said Dr. Marek Honczarenko

DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Keenova Therapeutics plc, a leading developer and manufacturer of branded therapeutics, announced today that it will report its third quarter 2026 financial results on Tuesday, November 10, 2026, before market open. The Company will host a conference call on the same day at 8:00 a.m. ET. The audio webcast may be accessed through the Investor Relations section of the Company's website at investor.keenova.com under Events & Presentations or through this link. To access the call through a conference line, participants can register here to receive a dial-in number and personalized PIN to partici

DUBLIN, Oct. 21, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that two presentations on hepatorenal syndrome-acute kidney injury (HRS-AKI) and TERLIVAZ® (terlipressin) will be shared at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 21-25, 2026. "These presentations add to the growing body of evidence supporting the use of TERLIVAZ in HRS-AKI," said Dr. Marek Honczarenko, Executive Vice President and Chief Scientific Officer at Keenova. "By examining treatment outcomes in both clinical trial and real-world settings, these analyses provide valuable insights that can help inform t

DUBLIN, Oct. 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ® (terlipressin) will be shared at the American College of Gastroenterology Annual Meeting, taking place October 9-14, 2026."We are pleased to share these findings with the medical community because they contribute to our understanding of this challenging and rapidly progressive condition," said Nancy Reau, MD, Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center and presenting author. "The exploratory analysis expands the clinical evidence on the use of terlipres

DUBLIN, Oct. 8, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that it will share data and insights related to men's health during three speaker presentations at the Sexual Medicine Society of North America annual meeting, taking place October 8-11, 2026.Two presentations will highlight clinical studies and real-world treatment experience supporting the use of XIAFLEX® (collagenase clostridium histolyticum) as a nonsurgical treatment option for men with Peyronie's disease, including those with ventral curvature.The third presentation will feature Keenova's Men's Sexual Health Screener, a clinician-patient communication resource designed to help facilitate more efficient assess

Monthlong campaign in September aims to elevate awareness of hand health, encourage early detection of Dupuytren's contracture, and connect patients with appropriate careDUBLIN, Sept. 1, 2026 /PRNewswire/ -- Keenova Therapeutics plc today announced plans for the 2nd Annual National Hand Health Month (HHM), a nationwide U.S. observance held each September that is dedicated to raising awareness about hand health and encouraging people to take action when they notice signs of hand conditions. "Our hands play a vital role in nearly everything we do," said Stephanie Wenstrup, Head of Marketing at Keenova. "National Hand Health Month

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toeNo FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toeHammer toe treatment today is limited to mainly orthotics, painkillers, or surgeryDUBLIN, Aug. 20, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that the first patient has been successfully enrolled and received study treatment in its Phase 3 clinical trial evaluating XIAFLEX® (collagenase clostridium histolyticum) as an investigational nonsurgical treatment for patients with hammer toe. While cons

Strong Performance Driven by Growth in Acthar® Gel1 and XIAFLEX®2XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026Percocet Divestiture to Complete Exit of Opioid BusinessRaises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year GrowthConference Call and Webcast Today at 8:00 a.m. ET Second Quarter 2026 Highlights3Acthar Gel net sales of $205 millionXIAFLEX net sales of $150 millionNet sales from continuing operations of $517 millionLoss from continuing operations of $22

DUBLIN, Aug. 3, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript examining whether baseline penile pain influences treatment outcomes in men with Peyronie's disease treated with XIAFLEX® (collagenase clostridium histolyticum). The Keenova‑sponsored posthoc analysis, which evaluated existing XIAFLEX clinical trial data, appears in Translational Andrology and Urology. "These findings highlight the importance of looking beyond pain alone when evaluating Peyronie's disease," said Landon Trost, MD, Director of the Male Fertility and Peyronie's Clinic in Orem, Utah, and senior author of the

DUBLIN, July 30, 2026 /PRNewswire/ -- Keenova Therapeutics plc, a leading developer and manufacturer of branded therapeutics, announced today that it will report its second quarter 2026 financial results on Tuesday, August 11, 2026, before market open. The Company will host a conference call on the same day at 8:00 a.m. ET. The audio webcast may be accessed through the Investor Relations section of the Company's website at investor.keenova.com under Events & Presentations or through this link. To access the call through a conference line, participants can register here to receive a dial-in number and personalized PIN to partici

DUBLIN, July 13, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript about the use of Acthar Gel (repository corticotropin injection) to treat certain severe autoimmune diseases. Sponsored by Keenova, the retrospective, physician-reported, survey-based medical chart review study covered in the manuscript used real‑world clinical data to evaluate patient characteristics, treatment patterns, and physicians' assessments of outcomes among individuals with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis/polymyositis (DM/PM) who received Acthar Gel. The manuscript appears in the peer-reviewed Journal of Comparative Effectiv

DUBLIN, July 8, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic medical condition that causes nodules composed primarily of excess collagen to form in the connective tissue that supports the arch of the foot. The ResultsThe pivotal trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in pain versus placebo, as measured by the Average Daily Pain Intensity on the Numeric Rating Scale (NRS).It also met key ra

Mallinckrodt plc (OTC:MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to access $150 million of the $250 million of commitments for new financing it received from certain of its creditors, as well as new borrowing availability from lenders under its asset-based loans. The approvals granted by the Court also enable the Company to continue paying employee wages, salaries and benefits without

Continuing to Serve Customers and Deliver High-Quality Therapies to Patients Without Interruption; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to ac

Reuters Walmart Settles Lawsuit Regarding Allegations Of Light-Bulb Patent Infringement Walmart Inc (NYSE:WMT) has reportedly resolved the University of California's light-bulb patent lawsuit. The university accused the retail behemoth of infringing its patents associated with "filament" LED light bulbs (invented at the Santa Barbara-based school system). The federal judge in Los Angeles would dismiss the case with prejudice, which means it cannot be refiled. Renault Eyes Spring 2024 IPO For EV Unit Ampere Renault SA (OTC:RNLSY) (OTC:RNSDF) is reportedly expecting to list its electric vehicle business unit, Ampere, on the stock market in the spring of 2024. Renault Chief Executiv

Mallinckrodt Plc (NYSE:MNK) has taken the next steps to implement the comprehensive financial restructuring plan. The company and some of its subsidiaries have filed for a second bankruptcy in three years in the U.S., with the newest restructuring plan set to reduce its debt by about $1.9 billion. The company expects to complete the court-supervised process in the fourth quarter of 2023. The RSA also provides for a final, one-time payment of $250 million, among other considerations.  In addition to the $450 million the company previously paid, this payment is intended to support the Trust's mission to address the U.S. opioid crisis and fund addiction treatment. The 156-year-old company 

The jury seeks information and data relating to the Company’s reporting of suspicious orders for controlled substances, chargebacks, and other transactions, and communications between the Company and the U.S. Drug Enforcement Administration regarding those issues.

Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First and Second Lien Debtholders Continuing to Operate Normally, Serve Customers and Deliver High-Quality Therapies to Patients Vendors and Suppliers Expected to be Paid in Full in the Ordinary Course DUBLIN, Aug. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the Company previously entered into with more than 85% of each of th

Rite Aid Corp (NYSE:RAD) is reportedly on the brink of filing for bankruptcy amidst many lawsuits over its purported role in the opioid crisis to address its significant debt burden, which exceeds $3.3 billion, through a Chapter 11 filing.  The drug retailer is grappling with over a thousand consolidated federal lawsuits in Ohio and numerous similar state lawsuits.  The Justice Department has slapped Rite Aid with a civil lawsuit, accusing it of dispensing controlled drugs violating the False Claims Act and Controlled Substances Act. Rite Aid's financial health has deteriorated with declining revenues and mounting losses. Furthermore, its shares plummeted by over 80% within a year. This

Gainers Cano Health (NYSE:CANO) shares rose 58.7% to $0.37 during Friday's regular session. As of 13:31 EST, Cano Health's stock is trading at a volume of 98.0 million, which is 1253.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $104.2 million. YS Biopharma Co (NASDAQ:YS) stock increased by 41.19% to $1.1. As of 13:31 EST, this security is trading at a volume of 38.1 million shares, making up 5860.1% of its average full-day volume over the last 100 days. The company's market cap stands at $102.3 million. Aptorum Gr (NASDAQ:APM) stock increased by 34.37% to $2.37. As of 13:31 EST, this security is trading at a volume of 6.2 mil

Gainers Apellis Pharmaceuticals (NASDAQ:APLS) shares rose 30.2% to $40.05 during Wednesday's regular session. Trading volume for Apellis Pharmaceuticals's stock is 9.9 million as of 13:31 EST. This is 229.8% of its average full-day volume over the last 100 days. The company's market cap stands at $4.7 billion. Aditxt (NASDAQ:ADTX) stock increased by 29.82% to $12.99. Trading volume for Aditxt's stock is 441.2K as of 13:31 EST. This is 745.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.4 million. ITeos Therapeutics (NASDAQ:ITOS) shares moved upwards by 26.63% to $14.88. Trading volume for ITeos Therapeutics's stock is 8.2 mil